CTLA4 and neoplasm: Ipililumab, an mAb directed against CTLA-4, was the first therapy to procure survival benefits for patients with metastatic melanoma (340), providing proof-of-concept that disrupting checkpoint molecules could alone reverse tumor immunoresistance and lead to immune-mediated tumor eradication.